Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Francisco Ayala-de la Peña"'
Autor:
Maria Carmen Rodenas, Julia Peñas-Martínez, Irene Pardo-Sánchez, David Zaragoza-Huesca, Carmen Ortega-Sabater, Jorge Peña-García, Salvador Espín, Guillermo Ricote, Sofía Montenegro, Francisco Ayala-De La Peña, Ginés Luengo-Gil, Andrés Nieto, Francisco García-Molina, Vicente Vicente, Francesco Bernardi, María Luisa Lozano, Victoriano Mulero, Horacio Pérez-Sánchez, Alberto Carmona-Bayonas, Irene Martínez-Martínez
Publikováno v:
Frontiers in Molecular Biosciences, Vol 10 (2023)
Introduction: Hepsin is a type II transmembrane serine protease and its expression has been linked to greater tumorigenicity and worse prognosis in different tumors. Recently, our group demonstrated that high hepsin levels from primary tumor were ass
Externí odkaz:
https://doaj.org/article/0a0bec65f1084dbb942a08af8b945209
Autor:
Alberto Carmona-Bayonas, Caterina Calderón, Raquel Hernández, Ana Fernández Montes, Beatriz Castelo, Laura Ciria-Suarez, Mónica Antoñanzas, Jacobo Rogado, Vilma Pacheco-Barcia, Elena Asensio Martínez, Alejandra Ivars, Francisco Ayala de la Peña, Paula Jimenez-Fonseca
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Quality of life (QoL) is a complex, ordinal endpoint with multiple conditioning factors. A predictive model of QoL after adjuvant chemotherapy can support decision making or the communication of information about the range of treatment optio
Externí odkaz:
https://doaj.org/article/8239bfeb60044c5d8981d76b9c9a0e1a
Autor:
Esmeralda García-Torralba, Esther Navarro Manzano, Gines Luengo-Gil, Pilar De la Morena Barrio, Asunción Chaves Benito, Miguel Pérez-Ramos, Beatriz Álvarez-Abril, Alejandra Ivars Rubio, Elisa García-Garre, Francisco Ayala de la Peña, Elena García-Martínez
Publikováno v:
Frontiers in Oncology. 13
BackgroundUp to 30% of breast cancer (BC) patients treated with neoadjuvant chemotherapy (NCT) will relapse. Our objective was to analyze the predictive capacity of several markers associated with immune response and cell proliferation combined with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b84e89035dfb742e8b42450e6cb7527
https://doi.org/10.3389/fonc.2023.1182725
https://doi.org/10.3389/fonc.2023.1182725
Autor:
Esmeralda García-Torralba, Miguel Pérez Ramos, Alejandra Ivars Rubio, Esther Navarro-Manzano, Noel Blaya Boluda, Pilar de la Morena Barrio, Elisa García-Garre, Francisco Martínez Díaz, Asunción Chaves-Benito, Elena García-Martínez, Francisco Ayala de la Peña
Publikováno v:
Cancers; Volume 15; Issue 10; Pages: 2846
Luminal breast cancer (BC) is associated with less immune activation, and the significance of stromal lymphocytic infiltration (sTIL) is more uncertain than in other BC subtypes. The aim of this study was to investigate the predictive and prognostic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcb0a063779405d6bfd0e97829ceef4f
Autor:
Coralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, Marta Roche-Molina, María del Monte-Millán, Tatiana Massarrah, Yolanda Jerez, Francisco Ayala de la Peña, José Ángel García-Sáenz, Fernando Moreno, Álvaro Rodríguez-Lescure, Diego Malón-Giménez, Ana Isabel Ballesteros García, Mercedes Marín-Aguilera, Patricia Galván, Fara Brasó-Maristany, Adrienne G. Waks, Sara M. Tolaney, Elizabeth A. Mittendorf, Ana Vivancos, Patricia Villagrasa, Joel. S. Parker, Charles M. Perou, Laia Paré, Guillermo Villacampa, Aleix Prat, Miguel Martín
Publikováno v:
JAMA Oncology.
ImportanceBiomarkers to guide the use of pertuzumab in the treatment of early-stage ERBB2 (formerly HER2)-positive breast cancer beyond simple ERBB2 status are needed.ObjectiveTo determine if use of the HER2DX genomic assay (Reveal Genomics) in pretr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e348a1083d2001a24b3efbe486c28c5
https://doi.org/10.1001/jamaoncol.2023.0187
https://doi.org/10.1001/jamaoncol.2023.0187
Autor:
Esmeralda Garcia-Torralba, Beatriz Álvarez-Abril, Carlos Bravo-Pérez, Esther Navarro Manzano, Pilar de la Morena Barrio, Alejandra Ivars Rubio, Elisa García-Garre, Gema Marín Zafra, Francisco Ayala de la Peña, Elena García-Martínez
Publikováno v:
Cancer Research. 82:P4-07
Introduction and objectives Up to 30% of early breast cancer (BC) patients treated with neoadjuvant chemotherapy will have systemic relapse during the follow-up. The integration of clinical, analytical and molecular parameters associated to tumor bio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1c9f399f781ed7c0377e3a0d37376a8
https://doi.org/10.1158/1538-7445.sabcs21-p4-07-03
https://doi.org/10.1158/1538-7445.sabcs21-p4-07-03
Autor:
Esmeralda Garcia-Torralba, Beatriz Álvarez-Abril, Carlos Bravo-Pérez, Esther Navarro Manzano, Pilar de la Morena Barrio, Alejandra Ivars Rubio, Elisa García-Garre, Gema Marín Zafra, Francisco Ayala de la Peña, Elena García-Martínez
Publikováno v:
Cancer Research. 82:P4-07
Introduction. There are still 30-40% of patients with early breast cancer (BC) that relapse after neoadjuvant chemotherapy (NAC). New prognostic biomarkers are needed. Current evidence shows that both markers of antitumor local and systemic immune re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::507ac1e5a2807465931c1c956b00edc3
https://doi.org/10.1158/1538-7445.sabcs21-p4-07-11
https://doi.org/10.1158/1538-7445.sabcs21-p4-07-11
Autor:
Ruth Vera, Oscar Juan-Vidal, María José Safont-Aguilera, Francisco Ayala de la Peña, Aránzazu González del Alba
Publikováno v:
Clinical and Translational Oncology.
Background Precision medicine in oncology aims to identify the most beneficial interventions based on a patient’s individual features and disease. However, disparities exist when providing cancer care to patients based on an individual’s sex. Obj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc0719f6360726f85d0a1dc83b103e40
https://doi.org/10.1007/s12094-023-03112-w
https://doi.org/10.1007/s12094-023-03112-w
Autor:
Elena García-Martínez, Melody Smith, Aitziber Buqué, Fernando Aranda, Francisco Ayala de la Peña, Alejandra Ivars, Manuel Sanchez Cánovas, Ma Angeles Vicente Conesa, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi
Publikováno v:
OncoImmunology, Vol 7, Iss 6 (2018)
Cytokines regulate virtually aspects of innate and adaptive immunity, including the initiation, execution and extinction of tumor-targeting immune responses. Over the past three decades, the possibility of using recombinant cytokines as a means to el
Externí odkaz:
https://doaj.org/article/6731cb15153b4509a97d8f6329ec4567
Autor:
Gines Luengo-Gil, Enrique Gonzalez-Billalabeitia, Sergio Alejo Perez-Henarejos, Esther Navarro Manzano, Asuncion Chaves-Benito, Elena Garcia-Martinez, Elisa Garcia-Garre, Vicente Vicente, Francisco Ayala de la Peña
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0194638 (2018)
BACKGROUND:Angiogenesis is a key process for tumor progression and a target for treatment. However, the regulation of breast cancer angiogenesis and its relevance for clinical resistance to antiangiogenic drugs is still incompletely understood. Recen
Externí odkaz:
https://doaj.org/article/dd106c7a60b943b68c3fd6b0448f99f6